TABLE 2.
ED50 of additive-free meglumine antimoniate for wild-type strain 1166 and SbV-resistant line selected in vitro and strains isolated from patients presenting relapse or reinfectiona
| Expt no. | Strain | ED50 (μg of SbV/ml) |
|---|---|---|
| 1 | Internal control | |
| 1166wt | 16.70 | |
| 1166SR | 140.22 | |
| Relapse | ||
| RE-2407i | >170.00 | |
| RE-2407r | 85.90 | |
| 2 | Internal control | |
| 1166wt | 39.50 | |
| 1166SR | 209.94 | |
| Relapse | ||
| RE-2025i | >170.00 | |
| RE-2025r | >680.00 | |
| RE-2238i | >170.00 | |
| RE-2238r | 170.00 | |
| 3 | Internal control | |
| 1166wt | 15.75 | |
| 1166SR | 209.50 | |
| Reinfection | ||
| RI-2309i | ND | |
| RI-2309r | 97.19 | |
| RI-2485i | 28.43 | |
| RI-2485r | 132.40 |
a
1166 wt, wild-type 1166; 1166SR, strain 1166 selected for SbV resistance; i, strain isolated from initial lesion; r, strain isolated from recurrent lesion; ND, not determined.